Dimerix has agreed to acquire Mission Therapeutics’ Phase 2-ready acute kidney injury asset, paying $5 million upfront and up to $287 million in milestones. The deal positions Dimerix to push the program toward a Phase 2 setting for broader development, while Mission’s pipeline focus shifts following the sale.